Literature DB >> 16563972

The cumulative effect of acute rejection on development of cardiac allograft vasculopathy.

Serban C Stoica1, Fay Cafferty, Mahesh Pauriah, Craig J Taylor, Linda D Sharples, John Wallwork, Stephen R Large, Jayan Parameshwar.   

Abstract

BACKGROUND: Acute rejection increases the inflammatory burden of the transplanted organ and predisposes to cardiac allograft vasculopathy (CAV). In this study we aim to determine the magnitude of the association, and to differentiate between the effects of mild vs severe rejection episodes.
METHODS: Between 1988 and 2003, 489 1-year survivors of heart transplantation underwent 1,435 angiograms. These patients were classified as having no CAV (0% stenosis), mild/moderate CAV (<70%) or severe CAV (>70%). Acute rejection was considered either mild (Grades 1A, 1B and 2 untreated) or moderate/severe (Grade 2 treated on a clinical basis and Grades 3A, 3B and 4). We used multi-state Markov models to examine risk factors for the onset of CAV.
RESULTS: Expressed as relative risk, the onset of CAV was significantly increased by donor age (1.26 per 10 years, 95% confidence interval [CI] 1.12 to 1.42), male recipient (1.72, 95% CI 1.01 to 2.94), pre-transplant recipient ischemic disease (1.53, 95% CI 1.14 to 2.06) and cumulative number of moderate/severe rejections (1.10 per episode, 95% CI 1.03 to 1.18). Human leukocyte antigen (HLA) and cytomegalovirus (CMV) matching, donor gender, recipient age, smoking, cumulative CMV infections and mild rejections were not significant risk factors. Estimated annual onset rate of CAV was 11.3% for patients with no moderate/severe rejection, rising to 13.6% for those with two and 18.0% for those with five such rejections.
CONCLUSIONS: Acute moderate/severe cellular rejection has a cumulative impact on CAV onset, whereas mild, untreated rejection is not associated with CAV.

Entities:  

Mesh:

Year:  2006        PMID: 16563972     DOI: 10.1016/j.healun.2005.11.449

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  15 in total

1.  Worsening in Longitudinal Strain and Strain Rate Anticipates Development of Pediatric Transplant Coronary Artery Vasculopathy as Soon as One Year Following Transplant.

Authors:  Richard J Boruta; Shelley D Miyamoto; Adel K Younoszai; Sonali S Patel; Bruce F Landeck
Journal:  Pediatr Cardiol       Date:  2017-09-25       Impact factor: 1.655

2.  Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: implications for donor allocation.

Authors:  Alykhan S Nagji; Tjasa Hranjec; Brian R Swenson; John A Kern; James D Bergin; David R Jones; Irving L Kron; Christine L Lau; Gorav Ailawadi
Journal:  Ann Thorac Surg       Date:  2010-07       Impact factor: 4.330

3.  Cardiac Allograft Rejection Induces Changes in Nucleocytoplasmic Transport: RANGAP1 as a Potential Non-Invasive Biomarker.

Authors:  Silvia Lozano-Edo; Esther Roselló-Lletí; Ignacio Sánchez-Lázaro; Estefanía Tarazón; Manuel Portolés; Maryem Ezzitouny; Raquel Lopez-Vilella; Miguel Angel Arnau; Luis Almenar; Luis Martínez-Dolz
Journal:  J Pers Med       Date:  2022-05-31

4.  Neutrophil mediated smooth muscle cell loss precedes allograft vasculopathy.

Authors:  Chelsey L King; Jennifer J Devitt; Timothy D G Lee; Camille L Hancock Friesen
Journal:  J Cardiothorac Surg       Date:  2010-06-22       Impact factor: 1.637

Review 5.  The complex role of iNOS in acutely rejecting cardiac transplants.

Authors:  Galen M Pieper; Allan M Roza
Journal:  Free Radic Biol Med       Date:  2008-02-07       Impact factor: 7.376

6.  Identification of common blood gene signatures for the diagnosis of renal and cardiac acute allograft rejection.

Authors:  Li Li; Kiran Khush; Szu-Chuan Hsieh; Lihua Ying; Helen Luikart; Tara Sigdel; Silke Roedder; Andrew Yang; Hannah Valantine; Minnie M Sarwal
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

Review 7.  Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis.

Authors:  Boško Skorić; Maja Čikeš; Jana Ljubas Maček; Željko Baričević; Ivan Škorak; Hrvoje Gašparović; Bojan Biočina; Davor Miličić
Journal:  Croat Med J       Date:  2014-12       Impact factor: 1.351

8.  Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells.

Authors:  Jiajia Cui; Lingfeng Qin; Junwei Zhang; Parwiz Abrahimi; Hong Li; Guangxin Li; Gregory T Tietjen; George Tellides; Jordan S Pober; W Mark Saltzman
Journal:  Nat Commun       Date:  2017-08-04       Impact factor: 14.919

9.  Host-derived smooth muscle cells accumulate in cardiac allografts: role of inflammation and monocyte chemoattractant protein 1.

Authors:  Piotr Religa; Monika K Grudzinska; Krzysztof Bojakowski; Joanna Soin; Jerzy Nozynski; Michal Zakliczynski; Zbigniew Gaciong; Marian Zembala; Cecilia Söderberg-Nauclér
Journal:  PLoS One       Date:  2009-01-14       Impact factor: 3.240

10.  Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients.

Authors:  Inger Johansson; Rune Andersson; Vanda Friman; Nedim Selimovic; Lars Hanzen; Salmir Nasic; Ulla Nyström; Vilborg Sigurdardottir
Journal:  BMC Infect Dis       Date:  2015-12-24       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.